Table 2.
Items | lncRNA ANRIL/miR‐125a axis | lncRNA ANRIL | miR‐125a | |||
---|---|---|---|---|---|---|
r | P value | r | P value | r | P value | |
BA‐E patients | ||||||
IgE | .163 | .125 | .126 | .238 | −.120 | .259 |
FEV1/FVC | −.621 | <.001 | −.395 | <.001 | .574 | <.001 |
FEV1%predicted | −.519 | <.001 | −.308 | .003 | .548 | <.001 |
BA‐R patients | ||||||
IgE | .150 | .158 | .064 | .548 | −.272 | .009 |
FEV1/FVC | −.210 | .047 | −.236 | .025 | .101 | .345 |
FEV1%predicted | .027 | .800 | .019 | .860 | −.055 | .606 |
Controls | ||||||
IgE | −.067 | .532 | −.055 | .609 | .083 | .436 |
FEV1/FVC | −.144 | .177 | .002 | .986 | .221 | .036 |
FEV1%predicted | .148 | .165 | .096 | .367 | −.128 | .228 |
Correlation between variables was determined by Spearman's rank correlation test. P value < .05 indicated a significant difference.
Abbreviations: BA‐E, bronchial asthma at exacerbation; BA‐R, bronchial asthma at remission; IgE, immune globulin E; FEV1, Forced expiratory volume in 1 second; FVC, forced vital capacity.